1. Home
  2. CSWC vs NTLA Comparison

CSWC vs NTLA Comparison

Compare CSWC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$22.03

Market Cap

1.3B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.86

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
NTLA
Founded
1961
2014
Country
United States
United States
Employees
30
N/A
Industry
Textiles
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
CSWC
NTLA
Price
$22.03
$12.86
Analyst Decision
Buy
Buy
Analyst Count
5
20
Target Price
$23.50
$20.45
AVG Volume (30 Days)
570.5K
3.9M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
11.92%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
$17.45
N/A
Revenue Next Year
$10.26
$62.75
P/E Ratio
$12.65
N/A
Revenue Growth
N/A
16.92
52 Week Low
$17.47
$5.90
52 Week High
$23.84
$28.24

Technical Indicators

Market Signals
Indicator
CSWC
NTLA
Relative Strength Index (RSI) 49.47 48.99
Support Level $21.30 $12.55
Resistance Level $23.19 $14.61
Average True Range (ATR) 0.47 0.74
MACD 0.02 -0.12
Stochastic Oscillator 75.44 50.96

Price Performance

Historical Comparison
CSWC
NTLA

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: